This trial is evaluating whether mRNA-1273 will improve 3 primary outcomes and 3 secondary outcomes in patients with COVID-19. Measurement will happen over the course of Up to Day 394 (1 year after second dose).
This trial requires 106 total participants across 5 different treatment groups
This trial involves 5 different treatments. MRNA-1273 is the primary treatment being studied. Participants will be divided into 5 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Participation is compensated
You will be compensated for participating in this trial.
There are many different treatments being used for covid-19, all depending on the patient. Treatment is based on symptom severity, immunity, and patient preference. There are multiple potential treatments. There is no one treatment that has been shown to work great for all people. There is no standard protocol for treatment. There are also many side effects from treatment, which can make decisions incredibly difficult for patients and their doctors. As this disease is under study there is not enough data to make long term treatment plans. Treatment for patients with covid-19 is focused on the specific patient.
Covid-19 is an infectious disease and should not be transmitted to others through sexual contact. It requires direct or close contact with either respiratory or gastrointestinal secretions or tissue from an ill person. These secretions can be collected through hand washing, which needs to be respected by healthcare workers and the public.
Signs associated with viral pneumonia include fever, a cough, and a sore throat. The rash and gastrointestinal signs, though present in the vast majority of cases, vary widely in their manifestation.\n
There is currently a lack of effective treatments for Covid-19 which is a serious threat to public health globally. Results from a recent clinical trial support our preliminary experimental finding by implicating the antihistamine Loperamide as a potential treatment option against SARS outbreak. We also show the utility of our drug discovery paradigm in predicting and testing compounds with high therapeutic value in other viral and prion illnesses.
Due to growing global public health concerns, we need to understand the underlying epidemiological, host and tissue factor (TF) related viral causes of disease. This is why we conducted an online survey using a combination of quantitative and qualitative techniques. In response, our survey has provided insights into the knowledge, attitudes, and practice of many medical professionals around an emerging zoonotic disease. The responses highlight that our professionals have limited knowledge around the disease, are not always satisfied or satisfied with their practice when dealing with an emerging public health concern. We need to understand why and what motivates good practitioners to embrace the practice of evidence-based medicine (EBM), especially in this challenging situation while ensuring health protection of the patients and the public.
In this sample of the US population, the risk of getting a mild case of a common respiratory infection is 0% per year; this has also been found in other countries.
Results from a recent paper demonstrated that MRC-1273 was commonly used as part of some treatments that are recommended by the Ministry of Health and Medical Education during 2019-2020 COVID-19 outbreak. The clinical use of MRC-1273 is limited by our study and will focus more research on this issue.
Given the nature and the prevalence of RNA-1273 related side effects, it is crucial to report to the ClinicalTrials.gov and publish all adverse effects as adverse events. Furthermore, the drug information page of mrna-1273 should specify all side effects of RNA-1273 that accompany every treatment, especially regarding the dosage and time interval of administration.
There are still more tests and therapies to go for patients. Some diseases are being studied more for their clinical signs and symptoms as compared with RNA interference-1273 and RNA interference (mice). We still need to make advancements. Results from a recent clinical trial of these studies can help other researchers to advance our understanding about this disease. Also, the results of these clinical trials can be reviewed so that we can find treatments that are more practical. As for the clinical trials that have been conducted so far, we need to increase our knowledge and speed up our advancements.
We have no evidence of a detrimental effect of this new virus strain in healthy adults. If symptoms do develop, they are usually mild, and a short term course, unless there is any underlying health problem, is usual.
The vast majority of reported clinical trials on coronavirus-related disease reported outcomes such as disease severity. Further, the limited number of people tested in these studies suggests that only a minority will have the condition to warrant testing, thus limiting access for people who may benefit from clinical trials. Clinical trials are an expensive resource. The burden of covid-19 will be severe for a huge fraction of the infected population. Consequently, the willingness of patients, clinicians and insurers to participate in clinical trials is an important concern.
RNA-1273 in combination with a standard of care for patients infected with SARS-CoV-2 demonstrated acceptable safety and preliminary efficacy which is supported by the preliminary analysis of a larger multicenter randomized controlled trial of patients with severe disease (median age 69.2, male 84%). While additional larger analyses of RNA-1273 are anticipated, this small trial is a step towards that goal.